Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is facing a series of patent challenges for some of its products. The company is looking to protect these products from generic competition by filing patent infringement lawsuits. However, these litigations lead to higher expenses. Companies often look to settle these challenges as it removes uncertainty regarding the timing of generic product launches and also cuts down on litigation costs. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is 2.62%. On last trading day company shares ended up $53.18. Analysts mean target price for the company is $57.09. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 5.33%.
Bristol-Myers Squibb Co (NYSE:BMY) announced a quarterly dividend on Tuesday, June 17th, Stock Ratings Network reports. Investors of record on Thursday, July 3rd will be paid a dividend of 0.36 per share on Friday, August 1st. This represents a $1.44 annualized dividend and a dividend yield of 3.03%. Bristol-Myers Squibb Co (NYSE:BMY) shares fell -0.46% in last trading session and ended the day on $47.84. BMY gross Margin is 72.40% and its return on assets is 8.00%.Bristol-Myers Squibb Co (NYSE:BMY) quarterly performance is -10.43%.
On June 18, 2014, ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) sent a letter to Institutional Shareholder Services (“ISS”) requesting that ISS reconsider its recommendation that the Company’s stockholders vote against the following proposals in the Company’s proxy statement for its 2014 annual meeting to be held on June 25, 2014. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares moved up 0.31% in last trading session and was closed at $6.57, while trading in range of $6.42 – $6.60. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) year to date (YTD) performance is -3.67%.
MannKind Corporation (NASDAQ:MNKD) VP Diane Palumbo sold 17,902 shares of the stock on the open market in a transaction dated Monday, June 16th. The shares were sold at an average price of $10.59, for a total value of $189,582.18. Following the sale, the vice president now directly owns 140,956 shares in the company, valued at approximately $1,492,724. MannKind Corporation (NASDAQ:MNKD) ended the last trading day at $10.52. Company weekly volatility is calculated as 3.41% and price to cash ratio as 114.19.MannKind Corporation (NASDAQ:MNKD) showed a positive weekly performance of 7.57%.
Roche Holdings Ltd (OTCMKTS:RHHBY) recently announced the acquisition of Genia Technologies in a bid to strengthen its diagnostics portfolio. Genia is involved in developing a next generation, single-molecule, semiconductor-based DNA sequencing platform using nanopore technology. Roche will make an upfront payment of $125 million in cash to Genia, with additional payments of up to $225 million on achieving certain development milestones. On last trading day company shares ended up $37.31.
Leave a Reply